| (USD) | Jun 2025 | Y/Y change |
|---|---|---|
| Revenue | 95.02M | 7.76% |
| Operating expense | — | — |
| Net income | 36.17M | 1.50% |
| Net profit margin | — | — |
| Earnings per share | — | — |
| EBITDA | — | — |
| Effective tax rate | — | — |
Over the past year, CUVL returned -10.4% with dividends reinvested.
| Period | Total return |
|---|---|
| YTD | -12.5% |
| 1 year | -10.4% |
| 5 years | -72.4% |
| 10 years | +90.2% |
| All-time high | $30.19 (Sep 2021) |
Returns are total returns and include reinvested dividends. The all-time high is the highest monthly closing price on record.
See what $1,000 in CUVL would be worth today ›No. Clinuvel Pharmaceuticals Limited has not paid a dividend in the past 12 months.
Clinuvel Pharmaceuticals Limited stock trades on NASDAQ under the ticker symbol CUVL.
Clinuvel Pharmaceuticals Limited is part of the Healthcare sector.
Clinuvel Pharmaceuticals Limited has a market cap of 374.18M USD, based on the latest quote.
Clinuvel Pharmaceuticals Limited, a biopharmaceutical company, focuses on developing and commercializing treatments for patients with genetic, metabolic, systemic, and life-threatening disorders in Australia, Europe, the United States, Switzerland, and internationally. Its lead drug candidate is SCENESSE, a systemic photoprotective drug for the prevention of phototoxicity in adult patients with erythropoietic protoporphyria (EPP). The company's pipeline products include CUV9900, an alpha-melanocyte stimulating hormone analogue; and PRÉNUMBRA, a liquid injectable formulation of afamelanotide. It is also developing NEURACTHEL (ACTH), an adrenocorticotropic hormone for targeting neurological, endocrinological, and degenerative disorders; and pharmaceutical formulations melanocortin technology for the treatment of a range of disorders. In addition, the company provides photocosmetic products for individuals and populations at risk of exposure to ultraviolet and high energy visible light, and in need of assistance in DNA repair and melanogenesis of the skin. The company was incorporated in 1999 and is headquartered in Melbourne, Australia.
